US equities
|
MU
$1,035.84
▲+0.00%
SPCX
$160.57
▲+0.00%
NVDA
$230.48
▲+0.00%
AAPL
$340.42
▲+0.00%
SNDK
$1,609.46
▲+0.00%
INTC
$107.08
▲+0.00%
AMD
$620.68
▲+0.00%
LITE
$1,048.60
▲+0.00%
MU
$1,035.84
▲+0.00%
SPCX
$160.57
▲+0.00%
NVDA
$230.48
▲+0.00%
AAPL
$340.42
▲+0.00%
SNDK
$1,609.46
▲+0.00%
INTC
$107.08
▲+0.00%
AMD
$620.68
▲+0.00%
LITE
$1,048.60
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Medicus Pharma Ltd. - Common Stock
(NQ:
MDCX
)
0.1019
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Medicus Pharma Ltd. - Common Stock
< Previous
1
2
3
4
Next >
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
October 08, 2026
Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
September 29, 2026
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategy
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
September 21, 2026
Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005, NDA-enabling, Registrational Phase 2b Study in Gorlin...
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
September 10, 2026
CSR provides a clinical foundation for the Company’s recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership...
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
September 08, 2026
Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
From
Medicus Pharma Ltd
Via
ACCESS Newswire
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
August 03, 2026
Dr. Mehmud’s appointment further aligns the scientific, clinical, regulatory and operational leadership of Antev
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
July 31, 2026
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health
From
Medicus Pharma Ltd
Via
GlobeNewswire
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
July 27, 2026
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended...
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings
July 25, 2026
From
New to The Street
Via
ACCESS Newswire
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
July 16, 2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
July 04, 2026
From
New to The Street
Via
ACCESS Newswire
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
June 22, 2026
Company’s presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the...
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
June 20, 2026
From
New to The Street
Via
ACCESS Newswire
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
June 15, 2026
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA
June 12, 2026
Via
ACCESS Newswire
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
June 11, 2026
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine...
From
Medicus Pharma Ltd
Via
GlobeNewswire
Graphene Manufacturing (OTCQX: GMGMF) (TSXV: GMG) Showcases Next-Generation Energy Storage and Graphene Innovation on Bloomberg TV – See INHD, SUNE, TDIC, DOSE Inside
June 08, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Energy
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
June 08, 2026
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annual market opportunity
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street Broadcasts Tonight on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM ET
June 06, 2026
Via
ACCESS Newswire
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
June 03, 2026
New Drug Application (NDA) enabling Phase 2b Protocol submission to the U.S. FDA Targets Rare Disease Population with Significant Unmet Need and Lifetime Burden of Repeated Skin Cancer Surgeries
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and Commodities
May 30, 2026
Via
ACCESS Newswire
Medicus Pharma Announces $22 Million Non-Dilutive Financing
May 28, 2026
Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years
From
Medicus Pharma Ltd
Via
GlobeNewswire
Alzheimer’s AI Biotech IGC Pharma, Inc. (NYSE: IGC) Stock in Focus – More Stocks Inside
May 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
May 23, 2026
Via
ACCESS Newswire
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma
May 16, 2026
Via
ACCESS Newswire
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives
From
Medicus Pharma Ltd
Via
GlobeNewswire
New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN)
May 09, 2026
Via
ACCESS Newswire
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 06, 2026
200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen
From
Medicus Pharma Ltd
Via
GlobeNewswire
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
May 01, 2026
Via
ACCESS Newswire
< Previous
1
2
3
4
Next >
